As we scale our global commercialization strategy, our network of trusted partners also continues to steadily grow. We’re proud to share that we are working with PS Pharma Service GmbH, a leading provider in Europe for pharmaceutical warehousing, logistics, manufacturing, and transportation. With more than 30 years of experience in the pharmaceutical ingredients market, PS Pharma will play a critical role in supporting our third-party logistics for our first products in Europe. We look forward to deepening this partnership as we continue our efforts to transform pharma supply chains with the power of biomanufacturing. #Antheia #Biomanufacturing #PharmaSupplyChains
Antheia, Inc.
Biotechnology Research
Menlo Park, California 7,183 followers
A synthetic biology company unlocking the medicinal power of nature - a platform for drug discovery and manufacturing
About us
Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole cell engineering reconstructing complex molecules in yeast to bring to market next generation plant inspired medicines. Antheia’s team of scientists and technologists is headquartered in Menlo Park, California. For more information, visit www.antheia.bio.
- Website
-
http://www.antheia.bio
External link for Antheia, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Menlo Park, California
- Type
- Privately Held
- Founded
- 2015
- Specialties
- metabolic engineering, fermentation, synthetic biology, drug discovery, and advanced manufacturing
Locations
-
Primary
1430 Obrien Dr
Suite A
Menlo Park, California 94025, US
Employees at Antheia, Inc.
Updates
-
Attending CPHI Global in Milan next week? Be sure to get in touch with our team via the CPHI app: Christina Smolke, Richard Sherwin, Guerin Kob, Yen-Hsiang W.. We’re looking forward to seeing you there and discussing all things #pharma #supplychains.
-
Ahead of CPHI Milan next month, CEO and Co-Founder Dr. Christina Smolke joined other dynamic industry leaders to discuss the critical role of diverse and inclusive leadership in pharma. She emphasized the importance of embracing diversity to deliver effective solutions: “No one group has a monopoly on good ideas, so we need to create more opportunities for problem-solvers of all backgrounds to lead the constant evolution and innovation this industry requires. With a more nuanced sense of healthcare challenges across demographics, we can improve health outcomes for more people.” Read her full thoughts here: https://bit.ly/3ZDPx2C If you’re attending CPHI Milan, be sure to add the panel “Leading with Diversity: The CEO Journey” on October 10 to your agenda to hear more from Christina and these leaders on advancing DEI in the pharma industry.
-
Today, we’re highlighting the public health impact of Narcan, a vital opioid overdose rescue drug that is now available over the counter. The FDA’s approval of OTC Narcan in 2023 was a major step forward in the fight to save lives, but scaling up production to meet increased demand is much easier said than done for the pharma industry. Read our latest blog post to learn more about the supply chain challenges impacting Narcan availability, and how biomanufacturing can help the industry respond more quickly to spikes in demand for essential medicines. https://bit.ly/3XTM7aK #Antheia #biomanufacturing #pharma #Narcan
-
CEO and co-founder, Dr. Christina Smolke will be taking the stage at CPHI Milan next month, discussing everything from global trends in biomanufacturing to 2025 outlooks for pharma to the importance of diversity and inclusion in the industry. Mark your calendars and we look forward to seeing you there! #Antheia #CPHIGlobal #CPHIMilan #biomanufacturing #pharmasupplychains
-
Next month, the Antheia team will be live at CPHI Global in Milan. If you’re looking to meet with Antheia at the conference, be sure to get in touch with our attending team members via the CPHI app: Christina Smolke, Guerin Kob, Richard Sherwin, and Yen-Hsiang W.. #Antheia #CPHIGlobal #CPHIMilan #biomanufacturing #pharmasupplychains
-
Next up in our #MeetTheTeam series, we’re pleased to introduce Ben Kotopka, Director of Data Science at Antheia. As our R&D team is constantly generating and collecting data, a comprehensive data strategy is essential -- without one, it is nearly impossible to successfully scale a new technology. Read more on what led Ben to work in data science and his views on this emerging field: https://bit.ly/474bucR #Antheia #DataScience #SyntheticBiology #PharmaSupplyChains
Introducing Ben Kotopka, Director of Data Science - Antheia
https://antheia.bio
-
This week, we had the pleasure of hosting a group of college students and graduates from the MelanInScience Tech Connect Summer Program at Antheia for a tour of our labs and a discussion with our team to learn about synthetic biology. MelanInScience was founded by the incredible Carmen Banks, PhD to build a brighter and more inclusive future for STEM and increase representation of marginalized communities in science. MelanInSience’s programs provide invaluable knowledge, mentorship, and resources to participants to help them pursue their own unique journey in STEM. We loved meeting this group of future scientists and can’t wait to see what they do! Learn more about MelanInScience: https://lnkd.in/eEqr6w32
-
The #Antheia team closed out the week with an epic game of water balloon toss at our family picnic! The competition was fierce, the grill was hot, and the vibes were high at Antheia HQ yesterday.
-
Antheia’s co-founder & CSO, Dr. Kristy Hawkins and COO, Zack McGahey recently sat down with Genetic Engineering & Biotechnology News to discuss Antheia’s proven approach of scaling novel biomanufacturing processes for critical pharmaceutical ingredients. For Antheia, scaling up means collaborating with industry partners, securing manufacturing capacity, and working with government bodies to onshore and stabilize pharmaceutical supply chains. On the heels of the company’s latest project agreement with the BioMaP-Consortium | Biopharmaceutical Manufacturing Preparedness Consortium, McGahey stated it perfectly: “We truly believe that the future of this technology should be here in the United States.” Read more about how Antheia is using synthetic biology to address supply chain cohesion, surety, and onshoring: https://bit.ly/46E67kv
Synthetic Biology at Scale: Less Disruption, More Cohesion
genengnews.com